Martin P J, Millac P A
Department of Neurology, Leicester Royal Infirmary, UK.
Seizure. 1994 Sep;3(3):209-13. doi: 10.1016/s1059-1311(05)80190-6.
We prospectively monitored our experience of lamotrigine as add-on therapy in 45 patients with refractory epilepsy. Nine patients (20%) withdrew from treatment due to adverse drug reactions and five patients (11%) withdrew because of a deterioration in seizure frequency. A further 17 patients (38%) showed little (< 25%) reduction in seizure number, eight patients (18%) showed a 25-50% reduction whilst 15 patients (33%) had a 50% or greater reduction in seizure number (P = 0.002). Lamotrigine was of greater benefit in patients with tonic-clonic seizures (seven of fourteen [50%] showed a > 50% seizure reduction; P = 0.01) than in patients with complex partial seizures (seven of 22 [32%] showed a > 50% seizure reduction; P = 0.02). Despite a high withdrawal rate due to ADRs, lamotrigine proved of significant benefit to one-third of our study group.
我们前瞻性地监测了45例难治性癫痫患者使用拉莫三嗪作为附加治疗的情况。9例患者（20%）因药物不良反应退出治疗，5例患者（11%）因癫痫发作频率恶化而退出。另有17例患者（38%）癫痫发作次数减少不足25%，8例患者（18%）癫痫发作次数减少25% - 50%，而15例患者（33%）癫痫发作次数减少50%或更多（P = 0.002）。拉莫三嗪对强直阵挛性发作患者（14例中有7例[50%]癫痫发作减少> 50%；P = 0.01）的益处大于复杂部分性发作患者（22例中有7例[32%]癫痫发作减少> 50%；P = 0.02）。尽管因不良反应导致停药率较高，但拉莫三嗪对我们研究组三分之一的患者有显著益处。
